Screener
Monte Rosa Therapeutics, Inc. GLUE Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $8.97M-61.3% | $4.21M-95.0% | $2.78M-95.4% | $12.77M+38.5% | $23.19M+394% | ||
| $47.96M+56.5% | $44.07M+36.9% | $41.98M+8.0% | $36.68M+32.8% | $30.65M+9.3% | ||
| $10.13M+25.2% | $10.18M+16.9% | $10.52M+19.8% | $9.07M+11.5% | $8.1M-12.8% | ||
| $58.1M+49.9% | $54.24M+32.6% | $52.5M+10.2% | $45.74M+28.0% | $38.75M+3.8% | ||
| -$49.13M-216% | -$50.03M-214% | -$49.72M— | -$32.98M-24.3% | -$15.55M+52.3% | ||
| -547.8%-481pp | -1,188.5%-1,240pp | -1,787.7%— | -258.3%+29.6pp | -67.1%+628pp | ||
| $5.92M+92.8% | $5.59M+62.6% | $3.69M+42.2% | $2.75M-5.0% | $3.07M+16.3% | ||
| $5.94M+33.3% | $5.58M+52.1% | $3.64M+40.1% | $2.72M-0.8% | $4.46M+72.5% | ||
| -$43.19M-289% | -$44.45M-193% | -$46.08M— | -$30.26M-27.2% | -$11.1M+63.1% | ||
| $208K-82.7% | $52K-93.7% | $0-100% | -$3.18M-4,575% | $1.2M+376% | ||
| -$43.4M-253% | -$44.5M-195% | -$46.11M— | -$27.08M-13.5% | -$12.3M+59.4% | ||
| -483.9%-431pp | -1,057.1%-1,112pp | -1,658%— | -212.1%+46.8pp | -53%+593pp | ||
| -$47.22M-252% | -$48.01M-204% | -$47.63M— | -$30.88M-26.4% | -$13.43M+56.1% | ||
| -526.5%-469pp | -1,140.3%-1,195pp | -1,712.6%— | -241.9%+23.2pp | -57.9%+593pp | ||
| -$49.13M-216% | -$50.03M-214% | -$49.72M— | -$32.98M-24.3% | -$15.55M+52.3% |
FAQ
- What is Monte Rosa Therapeutics, Inc.'s revenue?
- Monte Rosa Therapeutics, Inc. (GLUE) generated $28.7M in revenue over the trailing twelve months, down 83.9% year over year.
- Is Monte Rosa Therapeutics, Inc. profitable?
- Monte Rosa Therapeutics, Inc. is not currently profitable: it reported a net loss of $161.1M over the trailing twelve months, a -560.8% net margin.
- What is Monte Rosa Therapeutics, Inc.'s earnings per share?
- Monte Rosa Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.76.
- Where does Monte Rosa Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Monte Rosa Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
